PDEX · Pro Dex Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $66.59M | $53.84M | $46.09M | $42.04M | $38.03M | $34.83M |
| Cost of Revenue | $47.08M | $39.29M | $33.34M | $28.91M | $24.45M | $21.69M |
| Gross Profit | $19.51M | $14.55M | $12.75M | $13.13M | $13.57M | $13.14M |
| R&D | $3.64M | $3.19M | $2.80M | $2.98M | $4.38M | $2.31M |
| SG&A | $4.84M | $4.07M | $4.03M | $4.90M | $4.08M | $3.19M |
| Total Operating Expenses | $8.82M | $7.38M | $6.99M | $8.01M | $9.05M | $6.08M |
| D&A | $1.24M | $1.16M | $857.0K | $726.0K | $686.0K | $573.0K |
| Operating Income | $10.69M | $7.17M | $5.76M | $5.12M | $4.53M | $7.07M |
| Interest Expense | $829.0K | $558.0K | $533.0K | $464.0K | $352.0K | $236.0K |
| Income Tax | $3.08M | $507.0K | $2.35M | $851.0K | $1.18M | $1.79M |
| Net Income | $8.98M | $2.13M | $7.07M | $3.85M | $4.45M | $6.11M |
| EPS - Basic | $2.73 | $0.61 | $1.98 | $1.06 | $1.17 | $1.56 |
| EPS - Diluted | $2.67 | $0.60 | $1.95 | $1.02 | $1.13 | $1.50 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $419.0K | $2.63M | $2.94M | $849.0K | $3.72M | $6.42M |
| Accounts Receivable | $16.43M | $13.89M | $9.95M | $15.38M | $10.93M | $5.16M |
| Inventory | $22.21M | $15.27M | $16.17M | $12.68M | $8.44M | $8.24M |
| Accounts Payable | $4.61M | $4.51M | $2.26M | $3.76M | $2.29M | $1.97M |
| Current Assets | $47.30M | $36.61M | $30.98M | $31.17M | $25.01M | $22.67M |
| Total Assets | $61.19M | $52.48M | $51.82M | $47.33M | $40.32M | $31.13M |
| Current Liabilities | $14.63M | $12.89M | $9.68M | $11.35M | $5.87M | $5.23M |
| Long-term Debt | $15.43M | $11.96M | $12.80M | $13.59M | $12.84M | $3.98M |
| Total Liabilities | $24.56M | $21.61M | $20.23M | $23.66M | $20.24M | $12.06M |
| Stockholders' Equity | $36.63M | $30.87M | $31.59M | $23.67M | $20.08M | $19.06M |
| Retained Earnings | $35.93M | $26.95M | $24.82M | $15.99M | $12.35M | $7.90M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.68M) | $6.20M | $5.46M | ($847.0K) | ($2.08M) | $4.95M |
| Investing Cash Flow | ($238.0K) | ($2.23M) | ($885.0K) | ($1.24M) | ($3.71M) | ($2.29M) |
| Financing Cash Flow | ($292.0K) | ($4.27M) | ($2.49M) | ($790.0K) | $3.09M | ($3.98M) |
| CapEx | - | - | - | $1.64M | $1.77M | $519.0K |
| Free Cash Flow | - | - | - | ($2.48M) | ($3.85M) | $4.43M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 29.3% | 27.0% | 27.7% | 31.2% | 35.7% | 37.7% |
| Operating margin | 16.1% | 13.3% | 12.5% | 12.2% | 11.9% | 20.3% |
| EBITDA margin | 17.9% | 15.5% | 14.4% | 13.9% | 13.7% | 21.9% |
| Net margin | 13.5% | 4.0% | 15.3% | 9.2% | 11.7% | 17.5% |
| Free cash flow margin | - | - | - | -5.9% | -10.1% | 12.7% |
| FCF / Net income | - | - | - | -0.64 | -0.86 | 0.72 |
| R&D / Revenue | 5.5% | 5.9% | 6.1% | 7.1% | 11.5% | 6.6% |
| SG&A / Revenue | 7.3% | 7.6% | 8.7% | 11.7% | 10.7% | 9.2% |
| Effective tax rate | 25.5% | 19.2% | 25.0% | 18.1% | 20.9% | 22.7% |
| Return on assets | 14.7% | 4.1% | 13.7% | 8.1% | 11.0% | 19.6% |
| Return on equity | 24.5% | 6.9% | 22.4% | 16.3% | 22.2% | 32.1% |
| Return on invested capital | 15.3% | 13.5% | 9.7% | 11.3% | 10.9% | 23.7% |
| Liquidity | ||||||
| Current ratio | 3.23 | 2.84 | 3.20 | 2.74 | 4.26 | 4.34 |
| Quick ratio | 1.71 | 1.66 | 1.53 | 1.63 | 2.82 | 2.76 |
| Cash ratio | 0.03 | 0.20 | 0.30 | 0.07 | 0.63 | 1.23 |
| Leverage | ||||||
| Debt / Equity | 0.42 | 0.39 | 0.41 | 0.57 | 0.64 | 0.21 |
| Debt / Assets | 0.25 | 0.23 | 0.25 | 0.29 | 0.32 | 0.13 |
| Debt / EBITDA | 1.29 | 1.43 | 1.93 | 2.32 | 2.46 | 0.52 |
| Interest coverage | 12.9x | 12.9x | 10.8x | 11.0x | 12.9x | 29.9x |
| Equity multiplier | 1.67 | 1.70 | 1.64 | 2.00 | 2.01 | 1.63 |
| Liabilities / Assets | 0.40 | 0.41 | 0.39 | 0.50 | 0.50 | 0.39 |
| Efficiency | ||||||
| Asset turnover | 1.09 | 1.03 | 0.89 | 0.89 | 0.94 | 1.12 |
| Inventory turnover | 2.12 | 2.57 | 2.06 | 2.28 | 2.90 | 2.63 |
| Days sales outstanding | 90d | 94d | 79d | 134d | 105d | 54d |
| Days inventory outstanding | 172d | 142d | 177d | 160d | 126d | 139d |
| Days payable outstanding | 36d | 42d | 25d | 47d | 34d | 33d |
| Cash conversion cycle | 227d | 194d | 231d | 246d | 197d | 160d |
| Valuation | ||||||
| P / E | 16.3x | 32.7x | 9.8x | 15.6x | 27.0x | 11.9x |
| P / B | 4.0x | 2.3x | 2.2x | 2.5x | 6.0x | 3.8x |
| P / S | 2.2x | 1.3x | 1.5x | 1.4x | 3.2x | 2.1x |
| EV / EBITDA | 13.6x | 9.5x | 12.0x | 12.4x | 24.8x | 9.2x |
| Growth | ||||||
| Revenue growth (YoY) | 23.7% | 16.8% | 9.6% | 10.5% | 9.2% | 28.2% |
| Revenue CAGR (3y) | 16.6% | 12.3% | 9.8% | 15.7% | 19.2% | 16.7% |
| Revenue CAGR (5y) | 13.8% | 14.7% | 15.5% | 13.9% | 13.5% | 21.1% |
| Gross profit growth (YoY) | 34.1% | 14.1% | -2.9% | -3.3% | 3.3% | 34.4% |
| Operating income growth (YoY) | 49.0% | 24.5% | 12.5% | 13.2% | -36.0% | 41.4% |
| Net income growth (YoY) | 322.1% | -69.9% | 83.5% | -13.4% | -27.2% | 47.3% |
| EPS growth (YoY) | 345.0% | -69.2% | 91.2% | -9.7% | -24.7% | 54.6% |
| EPS CAGR (3y) | 37.8% | -19.0% | 9.1% | 1.7% | 45.1% | 6.3% |
| EPS CAGR (5y) | 12.2% | -9.2% | 39.4% | -4.0% | 41.4% | - |
| FCF growth (YoY) | - | - | - | 35.4% | - | 128.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 18.7% | -2.3% | 33.5% | 17.8% | 5.4% | 12.1% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
3.14
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing PRO DEX INC against the 5 most active filers in the same SIC group.